APA (7th ed.) Citation

N, C., AF, L., MZ, I., R, D., Y, C., S, R., . . . DW, H. (2025). Pharmacogenetics of plasma dolutegravir exposure during 1-month rifapentine/isoniazid treatment of latent tuberculosis. Pharmacogenetics and genomics, 35(4), 140. https://doi.org/10.1097/FPC.0000000000000562

Chicago Style (17th ed.) Citation

N, Covington, et al. "Pharmacogenetics of Plasma Dolutegravir Exposure During 1-month Rifapentine/isoniazid Treatment of Latent Tuberculosis." Pharmacogenetics and Genomics 35, no. 4 (2025): 140. https://doi.org/10.1097/FPC.0000000000000562.

MLA (9th ed.) Citation

N, Covington, et al. "Pharmacogenetics of Plasma Dolutegravir Exposure During 1-month Rifapentine/isoniazid Treatment of Latent Tuberculosis." Pharmacogenetics and Genomics, vol. 35, no. 4, 2025, p. 140, https://doi.org/10.1097/FPC.0000000000000562.